Correction: TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer

Código QR

Correction: TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer

Guardado en:

Detalles Bibliográficos
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/24dac64caa7b4976aaf3e616b2b967f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer
por: Michael Conroy, et al.
Publicado: (2021)

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer
por: Ciara H. O’Flanagan, et al.
Publicado: (2017)

Taxanes in the elderly patient with metastatic breast cancer
por: Yardley DA
Publicado: (2015)

Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites
por: Soojin Cha, et al.
Publicado: (2021)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
por: Yardley DA
Publicado: (2019)

Correction: Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Publicado: (2021)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publicado: (2021)

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Amanda Bortolini Silveira, et al.
Publicado: (2021)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014)

Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
por: Twelves C, et al.
Publicado: (2011)

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
por: Costanza Paoletti, et al.
Publicado: (2021)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Romualdo Barroso-Sousa, et al.
Publicado: (2021)

Advances in Immunotherapy and the TGF-β Resistance Pathway in Metastatic Bladder Cancer
por: David J. Benjamin, et al.
Publicado: (2021)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Lillian M. Smyth, et al.
Publicado: (2021)

Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12
por: Brile Chung, et al.
Publicado: (2017)

Correction: Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
Publicado: (2021)

Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
por: Jane Bayani, et al.
Publicado: (2017)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021)

Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer
por: Ying L. Liu, et al.
Publicado: (2021)

Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
por: Thomas Grinda, et al.
Publicado: (2021)

Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies
por: John F. R. Robertson, et al.
Publicado: (2021)

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
por: Linda T. Vahdat, et al.
Publicado: (2021)

Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy
por: Maria Vittoria Dieci, et al.
Publicado: (2021)

Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
por: Machado M, et al.
Publicado: (2012)

Correction: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
Publicado: (2021)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
por: Abdel Kader Y, et al.
Publicado: (2013)

Correction: Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model
Publicado: (2021)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Torsten Tonn, et al.
Publicado: (2021)

Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis
por: Martin C. Chang, et al.
Publicado: (2021)

Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer
por: Joseph T. Decker, et al.
Publicado: (2021)

CTEN Inhibits Tumor Angiogenesis and Growth by Targeting VEGFA Through Down-Regulation of β-Catenin in Breast Cancer
por: Xiangdong Lu PhD, et al.
Publicado: (2021)

Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Publicado: (2021)

IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer
por: Claudia Tulotta, et al.
Publicado: (2021)

Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial
por: Pamela J. Goodwin, et al.
Publicado: (2021)

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
por: Craig Davison, et al.
Publicado: (2021)

Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Jin Yuan MD, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Federica Miglietta, et al.
Publicado: (2021)

Correction to: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study
por: Mustafa Erman, et al.
Publicado: (2021)

Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment
por: Julia Stevenson, et al.
Publicado: (2021)

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Sanju Cyriac, et al.
Publicado: (2021)